Hengrui Pharmaceuticals’ Ivarmacitinib Approved for Rheumatoid Arthritis in China
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received additional indication approval...
Auto-immune
Jiangsu Hengrui Pharmaceuticals’ Ivarmacitinib Receives NMPA Approval for Ankylosing Spondylitis
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving marketing approval from the National...
Changchun High & New Technology Industries Receives US Trial Approval for GenSci120 in Rheumatoid Arthritis
China-based Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced its subsidiary GenScipt...
Accropeutics Closes RMB100 Million Series B+ Round to Advance Inflammatory Disease Pipeline
Accropeutics Inc., a clinical-stage biotech company with operations in New York, US, and Suzhou, China,...
Bio-Thera Solutions’ BAT2506 Biosimilar Accepted for Review by China’s NMPA
China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that a market filing for its BAT2506, a...
Biogen Initiates TRANSCEND Study for Felzartamab in Late AMR Kidney Transplant Patients
US-based Biogen Inc. (NASDAQ: BIIB) announced the initiation of the TRANSCEND study, a global Phase...
InnoCare Pharma Presents Positive Phase II Results of ICP-488 in Psoriasis at AAD Meeting
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced the oral presentation of results from the...
Roche’s Gazyva Receives FDA Review Acceptance for Lupus Nephritis Treatment
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced that the US Food and...
Bio-Thera Solutions Inks Licensing Deal with World Medicine for BAT2206
China-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with World Medicine, granting...
CARsgen Therapeutics Administers KJ-C2219 in SLE Patient in IIT
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that it has administered its KJ-C2219 at...
Suzhou Ribo Life Science’s RBD2080 siRNA Drug Receives Australian Clinical Trial Approval
China-based Suzhou Ribo Life Science Co., Ltd announced that its siRNA drug RBD2080 has received...
Sanofi and Teva’s Duvakitug Hits Key Milestones in UC and CD Study at ECCO Congress
Sanofi (EPA: SAN, NASDAQ: SNY) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) presented Phase IIb...
Triastek’s 3D-Printed Drug D23 Shows Promise in Treating IgA Nephropathy
China-based Triastek Inc., a pioneer in pharmaceutical 3D printing, announced positive outcomes from a clinical...
PolyMed Biopharma Licenses HPB-143 to Photys Therapeutics for Global Development
PolyMed Biopharma, a Hangzhou-based developer of Proteolysis Targeting Chimera (PROTAC) drugs, has entered into a...
Hengrui Pharma Submits Ivarmacitinib Ointment for AD Treatment Approval
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced the submission of a marketing filing for...
Huadong Medicine’s Biosimilar SaiYueXin Seeks NMPA Approval for Crohn’s Disease
Huadong Medicine Co., Ltd (SHE: 000963) announced that another indication approval filing for its SaiYueXin,...
Bio-Thera’s Biosimilars BAT2306 and BAT2506 Accepted for Review by NMPA and EMA
China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that the market filings for its biosimilars BAT2306...
Huahai Pharma Set to Launch IL-17 Antibody HB0017 Clinical Study for HS
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) is poised to initiate a clinical study...
Chongqing Genrix’s Xeligekimab Approved for Ankylosing Spondylitis by NMPA
China-based Chongqing Genrix Bio Pharmaceutical Co., Ltd (SHA: 688443) has announced receiving approval from the...
Fosun Pharma Initiates Phase II Study for Glomerular Disease Treatment
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the initiation of...